The Bridge Program equips researchers and entrepreneurs with the knowledge, skills and networks to successfully commercialise new pharmaceuticals.

Delivered by QUT, the Bridge Program is supported by a consortium of partners including leading pharmaceutical companies, universities, and industry affiliates. It leverages partner expertise and global connections to equip you with the skills and networks you need to take new medicines to market.

**WHY PARTICIPATE?**

- Access interactive online learning materials delivered by QUT at your own pace from anywhere around Australia.
- Connect with industry leaders in the Australian biotech ecosystem, and network with an alumni community of over 900 industry professionals at events like our three-day residential Symposium.
- Learn from the experts through our seminar series, presented by some of the biggest names in the business.
- Pitch your ideas and receive real-world feedback from industry experts in our pitch competition. Winners receive a fully-funded industry immersion experience.
- Access opportunities including our REDI Industry Fellowships Program.
- **There are no fees.** Our program is completely funded by industry partners and government as part of an initiative to grow Australia’s pharmaceutical and biotech industry capabilities.

**WHO SHOULD APPLY?**

Up to 100 participants are selected annually from across Australia. The program is suited to mid-career professionals looking to expand their commercialisation knowledge and networks including:

- researchers
- scientists
- entrepreneurs
- clinicians
- venture capitalists
- legal practitioners including IP lawyers and patent attorneys
- business development professionals
- staff from regulatory and government agencies

A background in pharmaceutical biotech and a demonstrated interest in a commercialisation career is essential.

**MORE INFORMATION**

Scan the QR code or visit our website to find out more about the Bridge Program: research.qut.edu.au/bridge/apply

**OUR PARTNERS**

This project is supported by MTPConnect through the Researcher Exchange and Development with Industry (REDI) Initiative.
This exclusive program provides access to international speakers and global leaders from top-tier pharmaceutical companies giving rise to collaborative commercialisation opportunities.

TESTIMONIALS
FROM OUR PARTICIPANTS:

“Despite my work experience with startups, the QUT Bridge program was immensely useful for me to further understand the depth & breadth of activities involved in commercialisation of research. The interactions with industry experts, peer-to-peer learning opportunities, & online modules were all well-arranged.

As a winner of the program’s pitch competition, I spent two weeks in the US visiting R&D facilities and meeting with senior managers from world-leading companies. This was a life-changing experience!”

“The program was really good and provided excellent opportunities to network not only with fellow Bridge participants but also with representatives from the pharma and commercialisation areas.

“I found both the on-line teachings and the residential component of the course as essential knowledge for any person involved in the drug development pipeline. The outcomes of the program will not be visible for many years but will save essentially thousands of hours of wasted research and development time, along with associated costs. It will give participants a commercial focus, which will result in more successful grants applications and industry/academic partnerships.”

“The program provided me with insight into the complex path of getting a drug on the market post the scientific research. I gained valuable skills to support academic researchers to position their work for commercialisation into a prevention or cure for disease.

“A private placement capital raising of AUD $15m was assisted, in part, by my introductions to executives in the investment community, and the skills which I gained (or reinforced) during the Bridge Program.”

“It was, and continues to be, a thoroughly enriching experience. It has tangible impact on the daily conduct of my work.”